Purpose To evaluate the effect of one TrueTear session on change in tear volume and symptoms of dryness and ocular pain.
Methods Retrospective interventional case series of patients seen in a dry eye clinic. Seventy-five individuals underwent an ocular surface examination and one session of neurostimulation. Outcome measures included objective change in tear volume measured via phenol red test, and subjective change in sensations of dryness and ocular pain measured on a 0–10 Numerical Rating Scale.
Results The mean age of the 75 individuals was 59±13 years, and the majority were male (73%). Intranasal neurostimulation increased tear volume (mean 13.40±8.00 mm, p<0.0005) and reduced intensities of dryness (mean −2.85±2.79, p<0.0005) and ocular pain (mean −1.48±2.41, p<0.0005 for both). However, these effects were independent of one another as change in symptom report did not correlate with change in tear volume (r=−0.13, p=0.25 for dryness; r=0.07, p=0.56 for pain). In a multivariable model, the strongest predictors for increased tear volume were lower baseline tear volume (standardised beta (β)=−0.50, p<0.0005) and absence of an autoimmune disease (β=−0.36, p=0.001) (R2=0.30). The strongest predictors for reduced dryness and pain scores were lower baseline dryness and ocular pain scores. No complications related to neurostimulation were noted.
Conclusion Intranasal neurostimulation increased tear volume and reduced intensities of dryness and ocular pain, independently of one another.
- ocular surface
- diagnostic tests/investigation
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Contributors All authors substantially contributed to this manuscript. Data collection: MF and AG. Data analysis: MF, AMC, AG and ERF. Drafting manuscript: MF, AC, BB and AG. Critical revision of manuscript: MF, AMC, BB, CDS, ERF, RCL and AG.
Funding This study was supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Clinical Sciences, Research EPID-006-15S, NIH Center Core grants P30EY014801 and R01EY026174 (AG), an unrestricted grant from Research to Prevent Blindness. Allergan provided the TrueTear equipment for the study but was not involved in the design, conduct or analysis of study results.
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.